SCHEMBL4848550

SCHEMBL4848550

NC1CCCN(Cc2ccc(Cl)cc2)C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.62
ALDH1A1 P00352 3/20 0.58
KDM4E B2RXH2 1/20 0.58
CYP2D6 P10635 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
BCHE P06276 1/20 0.47
ACHE P22303 1/20 0.47
BACE1 P56817 1/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 1/20 0.46
PKM P14618 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
NPC1 O15118 1/20 0.45
PDE2A O00408 1/20 0.44
DRD2 P14416 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25373516 1.00 GAA (0.62) GAAALDH1A1KDM4ECYP2D6CYP1A2
Hydrochloric Acid SCHEMBL4846915 0.98 GAA (0.61) GAAALDH1A1KDM4ECYP2D6CYP1A2
SCHEMBL4845501 0.95 ALDH1A1 (0.61) GAAALDH1A1KDM4ECYP2D6CYP1A2
SCHEMBL3810424 0.90 GAA (0.54) GAAALDH1A1KDM4ESIGMAR1BCHE
SCHEMBL3810502 0.90 GAA (0.54) GAAALDH1A1KDM4ESIGMAR1BCHE
SCHEMBL4427076 0.90 GAA (0.54) GAAALDH1A1KDM4ESIGMAR1BCHE
Hydrochloric Acid SCHEMBL4432892 0.88 GAA (0.52) GAAALDH1A1KDM4ESIGMAR1BCHE
Hydrochloric Acid SCHEMBL4425500 0.88 GAA (0.52) GAAALDH1A1KDM4ESIGMAR1BCHE
Hydrochloric Acid SCHEMBL4427412 0.88 GAA (0.52) GAAALDH1A1KDM4ESIGMAR1BCHE
SCHEMBL22254436 0.85 DRD4 (0.51) GAAALDH1A1SIGMAR1BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4204397-B1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LASB HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2025-12-03 EP disclosed
US-20230321123-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) 2023-10-12 US disclosed
EP-4204397-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LASB Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-07-05 EP disclosed
CN-116018337-A Pseudomonas aeruginosa virulence factor LasB inhibitor 亥姆霍兹感染研究中心有限公司 2023-04-25 CN disclosed
WO-2022043322-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2022-03-03 WO disclosed
US-7390830-B1 Remedies or prophylactics for diseases in association with chemokines TEIJIN LIMITED (JP) 2008-06-24 US disclosed
EP-1179341-B1 REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES TEIJIN LTD (JP) 2005-11-09 EP disclosed
EP-1553085-A1 Cyclic amine derivatives and their use as drugs TEIJIN LIMITED (JP) 2005-07-13 EP disclosed
EP-1535909-A2 Cyclic amine derivatives and their use as drugs TEIJIN LIMITED (JP) 2005-06-01 EP disclosed
CN-1384743-A Remedies or preventives for diseases in association with chemokines TEIJIN LTD (JP) 2002-12-11 CN disclosed
US-6451842-B1 Cyclic amine derivatives and their use as drugs DUPONT PHARMACEUTICALS COMPANY 2002-09-17 US disclosed
US-6410566-B1 ATHEROSCLEROSIS; ANTIARTHRITIC AGENTS TEIJIN LIMITED (JP) 2002-06-25 US disclosed
US-6362177-B1 INHIBITION OF CHEMOKINE BINDING TEIJIN LIMITED (JP) 2002-03-26 US disclosed
EP-1179341-A1 REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES TEIJIN LIMITED (JP) 2002-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321123-A1 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB SERPINB1, LTA, TFPI GAA 743/4885ALDH1A1 2662/4885KDM4E 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.